Clinical trial

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

NCT00440141

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention latanoprost 0.005% eye drops and brimonidine 0.1% eye drops Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-07-01

PhasePHASE4

Conditions

Glaucomaverified · MONDO: glaucoma

Ocular Hypertensionverified · MONDO: ocular hypertension

Interventions

latanoprost 0.005% eye drops and brimonidine 0.1% eye dropsDRUG

latanoprost 0.005% eye drops and brinzolamide 1.0% eye dropsDRUG

Sponsors & collaborators

Allerganlead sponsor

Mapped research locations

AtlantaGeorgia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00440141 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.